Trastuzumab and UHETA: Dual identities of the same drug

In the field of medicine, many drugs have more than one name and appear under different names in different places or markets. This is exactly the relationship between Fam-trastuzumab deruxtecan-nxki and Euched. They are actually two different names for the same drug.

Trastuzumab, as the drug’s scientific name reveals its chemical structure and properties. Uhaide is the trade name used in the Chinese market and is well known to the majority of patients and doctors. The existence of this dual identity not only reflects the unity of drugs on a global scale, but also adapts to the needs and habits of different markets.

Detrastuzumab precisely targets HER2-positive tumor cells by combining a humanized monoclonal antibody with a linker containing a cytotoxic drug. This unique mechanism of action allows trastuzumab to accurately deliver chemotherapy drugs to the tumor site, thereby minimizing side effects while ensuring the therapeutic effect. In clinical trials, trastuzumab has shown impressive results. It significantly extends survival and reduces the risk of disease progression in patients with HER2-positive breast cancer. At the same time, its safety has also been widely recognized, providing patients with a better quality of life guarantee.

The launch of trastuzumab undoubtedly brings new treatment hope to breast cancer patients. It is worth noting that although trastuzumab is already on the market in China, it is not currently covered by medical insurance. This means that patients need to bear high financial pressure when using this drug.